

TELEPHONE: 512/536-4598
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:
GSHISHIMA@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:
512/536-3081

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

BEST AVAILABLE COPY

March 26, 2002

FILE: UTSD:795US

10101381

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
March 26, 2002 Date	Steven L. Highlander

BOX MISSING PARTS

Commissioner for Patents
Washington, DC 20231

RE: *U.S. Patent Application No. 09/845,612 Entitled: A CLASS OF 12 MER PEPTIDES THAT INHIBIT THE FUNCTION OF THE MITOTIC CHECK POINT PROTEIN MAD2 - by Hongtao Yu et al.*
(Client Reference No. UTSD:795US)

Commissioner:

Enclosed for filing in the above-referenced patent application is:


- (1) Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- (2) Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Dated February 8, 2002;
- (3) Statement as Required Under 37 C.F.R. § 1.821(f); Paper Copy of Sequence Listing; Computer Readable Form (CRF); and
- (4) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Commissioner for Patents
March 26, 2002
Page 2

BEST AVAILABLE COPY

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10101381/SLH.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642

SLH/cpj
Encl.: As stated

BEST AVAILABLE COPY



APR 10 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/845,612	04/30/2001	Hongtao Yu	UTSD:0795

Steven L. Highlander
 Fulbright & Jaworski L.L.P.
 Suite 2400
 600 Congress Avenue
 Austin, TX 78701

RECEIVED
 Docketed: 4/18/02
 Filing Date: 4/18/02
 Filing Office: 0795
 FEB 15 2002
 Client: UTSD: 795
 Attorney(s): DPH
 Initials: [Signature]

CONFIRMATION NO. 2625

FORMALITIES LETTER



OC000000007451156

Date Mailed: 02/08/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov


A copy of this notice MUST be returned with the reply.

Customer Service Center
 Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



#11

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C., 20231, on the date below:	
March 26, 2002 Date	 Steven L. Highlander

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:
HONGTAO YU ET AL.

Serial No.: 09/845,612

Filed: APRIL 30, 2001

For: A CLASS OF 12MER PEPTIDES THAT
INHIBIT THE FUNCTION OF THE
MITOTIC CHECK POINT PROTEIN
MAD2

Group Art Unit: 1646

Examiner: UNKNOWN

Atty. Dkt. No.: UTSD:795US/SLH

STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(f)**BOX SEQUENCE**

Commissioner for Patents
Washington, D.C. 20231


Commissioner:

Submitted herewith is a computer readable form and a paper copy of the sequence listing of those sequences in the captioned patent application. The computer readable form of the sequence listing is the same as the paper copy of the sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed computer readable and paper forms of the sequence listing.

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3184

Date: March 26, 2002

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Steven L. Highlander", written over a circular stamp or seal.

Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants